Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05737602 · ClinicalTrials.gov registry record · NA
Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
A NA study, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT05737602: Active NA study, sponsored by Massachusetts General Hospital.
NCT05737602 is a NA study that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05737602, a NA study, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.
Interventions
- BEHAVIORAL 3RP-VHL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-07-30 |
| Est. Completion | 2028-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05737602
The ClinicalTrials.gov registry entry for NCT05737602 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3RP-VHL is the first listed.
NCT05737602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05737602 about?
NCT05737602 is a clinical study titled "Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease". The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of t...
What is the current status of trial NCT05737602?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-07-30. Estimated completion is 2028-07-01.
What interventions are being tested in trial NCT05737602?
The interventions under investigation include: 3RP-VHL (BEHAVIORAL).
Who is sponsoring clinical trial NCT05737602?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.